Programmed Cell Death Ligand 1–Induced Coma From Diffuse Cerebritis

Abstract

The article presents a case study of a 59-year-old woman who undergo a full septic workup and broad-spectrum antibiotics and intravenous (IV) hydration due to coma and dysautonomia. It mentions that the patient has a widely metastatic colon cancer who participates in a programmed cell death ligand 1 inhibitor atezolizumab's clinical trial. It discusses the condition which was commonly caused by diffuse cerebritis.